search
Back to results

Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome (CELEST)

Primary Purpose

Deep Vein Thrombosis, Post-thrombotic Syndrome

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
25mmHg ECS
35 mmHg ECS
Sponsored by
Laboratoires Innothera
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Deep Vein Thrombosis focused on measuring post-thrombotic syndrome, prevention, deep vein thrombosis, elastic compression stockings, compliance, quality of life

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  • Patient (male/female) at least 18 years old
  • Patient presenting with an initial episode of proximal deep vein thrombosis (DVT) confirmed by an additional examination (echo-Doppler scan) taken no more than 8 days previously :

the proximal character defined by a DVT from the collecting trunk extending from the tibial-peroneal trunk to the inferior vena cava inclusive the unilateral character concerns only the proximal part. Patients with a distal DVT on the contralateral member the day of diagnosis can be included The notion of initial episode concerns only the proximal part. Patients with a preceding DVT limited to distal part can be included

  • with no trophic disorders at baseline (CEAP class 4, 5 or 6 excluded)
  • with or without pulmonary embolism
  • Patient capable of benefiting from anticoagulant therapy of at least 3 months duration
  • Available to participate in a clinical trial with a 24-month follow-up period and for which a delivery of study products may be possible throughout its participation (delivery possible only in Metropolitan France)
  • Life expectancy greater than 24 months
  • Volunteer to take part in the study, having signed the consent form after receiving sufficient information and the information leaflet
  • Person affiliated to social security or the recipient of a similar scheme.

non inclusion criteria

  • Patients with at least one of these contraindications to compression treatment:

    • phlegmasia cerulea dolens,
    • septic thrombosis,
    • product intolerance, allergic reaction to one of the components
    • Arteritis obliterans stage III and IV of the lower limbs (IPS<0.6),
    • Micro-angiopathy, advanced diabetes,
    • Decompensated heart failure,
    • Skin infections: anti-infective treatment must precede compression therapy,
    • Weeping skin diseases of the leg.
    • Compression treatment technically impossible during the study
  • Patients presenting with bilateral venous thrombosis of the lower limbs.
  • Patient having received fibrinolytic treatment, mechanical thrombo-aspiration or venous repermeation surgery for venous thrombosis justifying inclusion
  • Patients having undergone mechanical interruption of the inferior vena cava.
  • Patients for whom long-term elastic compression for the treatment of lymphatic venous insufficiency (patients with lymphoedema), for instance, is indicated prior to DVT. Patients with elastic compression for primary thromboprophylaxis of thromboembolic disease (TED) are eligible.
  • Patients presenting with oedema unrelated to venous insufficiency or in whom oedema is likely to develop within 2 years.
  • Patients receiving diuretic treatment for more than 3 months due to heart failure.
  • Pregnant women
  • Person deprived of liberty by a legal or administrative decision, person under legal protection.
  • Patient currently participating in a clinical trial or having taken part in a clinical trial in the month preceding inclusion
  • Patient presenting with a history of mental or psychiatric illness or any other factor restricting his/her ability to participate in an informed manner and in compliance with the protocol

Sites / Locations

  • Cabinet
  • Cabinet
  • Cabinet
  • Clinique Victor PAUCHET
  • CHRU Amiens
  • Cabinet
  • Chu Angers
  • Cabinet
  • Chra Annecy
  • Centre Hospitalier d'Armentieres
  • CH Armentières
  • Cabinet
  • Cabinet
  • Ch Bourgoin-Jallieu
  • Hia Brest
  • Chu Brest
  • CHU
  • Cabinet
  • Cabinet
  • Ch Chalon Sur Saone
  • CH de Chambéry
  • Cabinet
  • Chu Clermont-Ferrand
  • CHU Gabriel Montpied
  • Cabinet
  • Hôpital du bocage
  • Cabinet
  • Cabinet
  • Cabinet
  • Chu Grenoble
  • Cabinet
  • Cabinet
  • Ch La Rochelle
  • Cabinet
  • Chru Lille
  • Hopital Saint Philibert
  • CH Pierre-Bénite
  • Cabinet
  • Cabinet
  • Cabinet
  • Cabinet
  • Chu Montpellier
  • CH Mâcon
  • Chu Hotel Dieu
  • CHR Orléans
  • HEGP
  • Hôpital St Joseph
  • Cabinet
  • Cabinet
  • Cabinet
  • Cabinet
  • Chu St Etienne
  • Cabinet
  • Chu Toulouse
  • Cabinet
  • Cabinet
  • Cabinet

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

25mmHg ECS

35mmHg ECS

Arm Description

Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years

Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years

Outcomes

Primary Outcome Measures

To show that elastic compression with ankle pressure targeted at 25 mm Hg is not inferior in preventing the onset of clinical post-thrombotic syndrome to a target ankle pressure of 35 mm Hg (recommended pressure being greater than 30 mm Hg)
cumulative incidence 24 months after inclusion of PTS apparition defined by the Villalta score > or equal to 5. A visual guide will be given to investigators to assist them and standardize PTS evaluation. Investigators will receive a Villalta training during set up visits.

Secondary Outcome Measures

superiority of targeted pressure at 35 mm Hg for compliant patients. Analysis of the primary endpoint per protocol amongst patients responding to the definition of compliance for compression scheduled by randomization
analysis of primary endpoint (cumulative incidence of PTS) amongst patients responding to the definition of observance for compression scheduled by randomization. It means a per protocol analysis. The per protocol analysis defined as follow : patients ideally compliant (see next secondary outcome measure with self declaration of compression carrying superior or equal to 80 % especially)and patients with respect to randomization.
Superiority of 25 mm Hg on the therapeutic compliance criterion
Superiority of 25 mm Hg on the therapeutic compliance criterion at 24 months Compliance is defined by 2 conditions : Girerd adapted to elastic compression stocking score adjusted between 0 and 2 (the question 2 will not be taken into account beacause not adapted to the logistics of the study) because of French clinical practices it should be pertinent to take into consideration 2 compliance type : ideal compliance : Self declaration ≥ 80 % (reference PRANDONI) adequate compliance : self declaration between 50 and 79% for (French references Delluc and Optimev study)
superiority of 25 mm Hg for constraints related to compression and chronic venous insufficiency quality of life (CIVIQ)
CIVIQ quality of life (CIVIQ 20) specific to chronic venous insufficiency at 3 months, 12 months and 24 months and questionnaire about constraints of compression stockings.
non inferiority of 25 mm Hg for the comparative evaluation of the symptomatic effect of short-term compression (pain, sensation of oedema) form baseline to 3 months
Comparison of evolution at short-term (3 months) of venous thrombosis symptoms (pain, oedema feeling). Self assessment by VAS of pain and oedema feeling once a week during 3 months. Assessment by the investigator at inclusion and during visit at 3 months (ankle measurement, clinical signs) will be done also. A statistical analysis will be done as soon as 3 months follow up data will be verified to evaluate symptoms evolution due to deep venous thrombosis.
Non-inferiority of 25 mm Hg for changes in overall quality of life evaluated on the basis of the EUROQUOL questionnaire
Non-inferiority of 25 mm Hg for changes in overall quality of life evaluated on the basis of the EUROQUOL questionnaire (EQ5D)
non inferiority of 25 mm Hg for the intensity of long term chronic venous insufficiency symptoms (12 months and 24 months)
Long term assessment of evolution and intensity of symptoms (pain, oedema feeling) related to potential post-thrombotic syndrome apparition Monthly self-assessment by VAS for pain and oedema feeling during 24 months. It will be done at the end of each month and will focus on symptoms intensity (last week of the month) An assessment will be done by investigator, in addition of previous criterion, at 12 and 24 months Assessment with the Ginsberg score (interview by the investigator at 12 and 24 months) Comparison of averages on Villalta score (quantitative)
non inferiority of 25 mm Hg for the onset of permanent trophic disorders
CEAP classification evaluated by investigator at 3, 12 and 24 months
non inferiority of 25 mm Hg for the onset of sequalae or post thrombotic residues on an duplex scan at 3 months, 12 and 24 months
Assessment by duplex scan of deep and superficial veins at 3, 12 and 24 months Assessment by duplex scan of deep reflux (>1s in femoral vein, and/or popliteal vein, tibio peroneal trunck) Assessment by duplex scan of superficial reflux (> 0.5s in great saphenous vein, small saphenous vein, perforating veins) Assessment by echographic score of thickness and location of residual thrombus Assessment by duplex scan of re-canalization of collectors trunks and/or parietal sequalae
testing for the prognostic factors of the onset post thrombotic syndrome and comparison of the onset kinetics of post thrombotic syndrome
variables tested as prognostic factors of post thrombotic syndrome apparition : location of the upper pole of thrombus kinetic of thrombus lysis by duplex scan at 3 months Idiopathic nature of TED Delay of diagnostic of deep venous thrombosis Initial intensity of deep venous thrombosis symptoms Initial evolution of symptoms of deep venous thrombosis between J0 and 3 months Persistence of the symptoms at 3 months Patient's characteristics Kinetic of of Villalta score apparition ≥ 5 by survival curve Kinetic of post thrombotic syndrome apparition by Villalta score
test for key factors in good compliance
Compliance evaluation according to the 2 axes defined on third outcome measure and research of determinants of good compliance by specific questionnaire
Adverse events
description and comparison of the incidence of adverse events including unexpected adverse events, events expected with this type of disease (recurrence of the venous thromboembolic disease, recurrence of deep vein thrombosis, pulmonary embolism, superficial venous thrombosis, venous ulcer) and events possibly related to the study treatment (arterial decompensation passing to Lerich stage III or IV, skin intolerance)
Subgroups analysis of the primary objective and secondary objectives according to the gender stratification criterion and age
Stratification on age (more or less than 65 years-old) for testing the hypothesis by subgroups analysis of the benefit of a better adaptation of compression 25 mm Hg on older subjects, as suggested by S. Khan.
superiority of 25 mmHg on 35 mmHg in preventing the onset of clinical post thrombotic syndrome
superiority of 25 mmHg on 35 mmHg in preventing the onset of clinical post thrombotic syndrome. Outcome measure identical to primary endpoint
sensitivity analysis of primary endpoint excluding patients with a differential diagnosis can explain a Villalta score ≥ 5
sensitivity analysis of primary endpoint excluding patients with a differential diagnosis which could explain a Villalta score ≥ 5. Outcome measure identical to primary endpoint

Full Information

First Posted
April 13, 2012
Last Updated
January 21, 2020
Sponsor
Laboratoires Innothera
Collaborators
University Hospital, Grenoble, Floralis
search

1. Study Identification

Unique Protocol Identification Number
NCT01578122
Brief Title
Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome
Acronym
CELEST
Official Title
Evaluation of the Efficacy of Elastic Compression in Preventing Post-thrombotic Syndrome. Randomised Non-inferiority Study for Ankle Pressure Targeted at 25 mm Hg Versus 35 mm Hg
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
June 29, 2012 (Actual)
Primary Completion Date
June 28, 2019 (Actual)
Study Completion Date
June 28, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Laboratoires Innothera
Collaborators
University Hospital, Grenoble, Floralis

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Post thrombotic syndrome (PTS) is a frequent and burdensome complication of proximal deep-vein thrombosis.Therapeutic options for PTS are limited and mainly rely on its prevention. Therapeutic trials evidenced that elastic compression stockings (ECS) applying 30-40mmHg of pressure at the ankle reduced the rate of PTS by 50%. Although ECS are unlikely to cause harm, in clinical practice, compliance to this treatment appears to be low as ECS may be difficult to apply and to wear. ECS with a lighter compression strength (20-30mmHg) might be easier to apply and be more comfortable. This could favor a better compliance. CELEST is a randomized, multicentre, double-blind trial which aims to determine whether ECS applying 25mmHg of targeted pressure at the ankle are non inferior to ECS applying 35mmHg of targeted pressure at the ankle
Detailed Description
CELEST trial is a controlled, randomized, multicentre, non-inferiority double-blind trial which aims to determine whether ECS applying 25mmHg of targeted pressure at the ankle are non inferior to ECS applying 35mmHg of targeted pressure at the ankle. Patients with a first acute symptomatic proximal DVT will be randomized to wear for two years either ECS applying 25mmHg of targeted pressure at the ankle or ECS applying 35mmHg of targeted pressure at the ankle. All patients will be prescribed anticoagulants for at least three months. The primary outcome will be the rate of PTS assessed with the Villalta scale in both arms of the study during the 2 years study period. Rate of compliance,severity of PTS and quality of life in both groups will constitute the main secondary outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Deep Vein Thrombosis, Post-thrombotic Syndrome
Keywords
post-thrombotic syndrome, prevention, deep vein thrombosis, elastic compression stockings, compliance, quality of life

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
350 (Actual)

8. Arms, Groups, and Interventions

Arm Title
25mmHg ECS
Arm Type
Experimental
Arm Description
Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years
Arm Title
35mmHg ECS
Arm Type
Active Comparator
Arm Description
Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years
Intervention Type
Device
Intervention Name(s)
25mmHg ECS
Other Intervention Name(s)
ACTYS 25® for women, LEGGER 25® for men
Intervention Description
Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years. Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
Intervention Type
Device
Intervention Name(s)
35 mmHg ECS
Other Intervention Name(s)
ACTYS 35® for women, LEGGER 35® for men
Intervention Description
Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
Primary Outcome Measure Information:
Title
To show that elastic compression with ankle pressure targeted at 25 mm Hg is not inferior in preventing the onset of clinical post-thrombotic syndrome to a target ankle pressure of 35 mm Hg (recommended pressure being greater than 30 mm Hg)
Description
cumulative incidence 24 months after inclusion of PTS apparition defined by the Villalta score > or equal to 5. A visual guide will be given to investigators to assist them and standardize PTS evaluation. Investigators will receive a Villalta training during set up visits.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
superiority of targeted pressure at 35 mm Hg for compliant patients. Analysis of the primary endpoint per protocol amongst patients responding to the definition of compliance for compression scheduled by randomization
Description
analysis of primary endpoint (cumulative incidence of PTS) amongst patients responding to the definition of observance for compression scheduled by randomization. It means a per protocol analysis. The per protocol analysis defined as follow : patients ideally compliant (see next secondary outcome measure with self declaration of compression carrying superior or equal to 80 % especially)and patients with respect to randomization.
Time Frame
24 months
Title
Superiority of 25 mm Hg on the therapeutic compliance criterion
Description
Superiority of 25 mm Hg on the therapeutic compliance criterion at 24 months Compliance is defined by 2 conditions : Girerd adapted to elastic compression stocking score adjusted between 0 and 2 (the question 2 will not be taken into account beacause not adapted to the logistics of the study) because of French clinical practices it should be pertinent to take into consideration 2 compliance type : ideal compliance : Self declaration ≥ 80 % (reference PRANDONI) adequate compliance : self declaration between 50 and 79% for (French references Delluc and Optimev study)
Time Frame
24 months
Title
superiority of 25 mm Hg for constraints related to compression and chronic venous insufficiency quality of life (CIVIQ)
Description
CIVIQ quality of life (CIVIQ 20) specific to chronic venous insufficiency at 3 months, 12 months and 24 months and questionnaire about constraints of compression stockings.
Time Frame
3 months, 12 months, 24 months
Title
non inferiority of 25 mm Hg for the comparative evaluation of the symptomatic effect of short-term compression (pain, sensation of oedema) form baseline to 3 months
Description
Comparison of evolution at short-term (3 months) of venous thrombosis symptoms (pain, oedema feeling). Self assessment by VAS of pain and oedema feeling once a week during 3 months. Assessment by the investigator at inclusion and during visit at 3 months (ankle measurement, clinical signs) will be done also. A statistical analysis will be done as soon as 3 months follow up data will be verified to evaluate symptoms evolution due to deep venous thrombosis.
Time Frame
3 months
Title
Non-inferiority of 25 mm Hg for changes in overall quality of life evaluated on the basis of the EUROQUOL questionnaire
Description
Non-inferiority of 25 mm Hg for changes in overall quality of life evaluated on the basis of the EUROQUOL questionnaire (EQ5D)
Time Frame
3months, 12 months, 24 months
Title
non inferiority of 25 mm Hg for the intensity of long term chronic venous insufficiency symptoms (12 months and 24 months)
Description
Long term assessment of evolution and intensity of symptoms (pain, oedema feeling) related to potential post-thrombotic syndrome apparition Monthly self-assessment by VAS for pain and oedema feeling during 24 months. It will be done at the end of each month and will focus on symptoms intensity (last week of the month) An assessment will be done by investigator, in addition of previous criterion, at 12 and 24 months Assessment with the Ginsberg score (interview by the investigator at 12 and 24 months) Comparison of averages on Villalta score (quantitative)
Time Frame
12 and 24 months
Title
non inferiority of 25 mm Hg for the onset of permanent trophic disorders
Description
CEAP classification evaluated by investigator at 3, 12 and 24 months
Time Frame
3 months, 12 and 24 months
Title
non inferiority of 25 mm Hg for the onset of sequalae or post thrombotic residues on an duplex scan at 3 months, 12 and 24 months
Description
Assessment by duplex scan of deep and superficial veins at 3, 12 and 24 months Assessment by duplex scan of deep reflux (>1s in femoral vein, and/or popliteal vein, tibio peroneal trunck) Assessment by duplex scan of superficial reflux (> 0.5s in great saphenous vein, small saphenous vein, perforating veins) Assessment by echographic score of thickness and location of residual thrombus Assessment by duplex scan of re-canalization of collectors trunks and/or parietal sequalae
Time Frame
3, 12 and 24 months
Title
testing for the prognostic factors of the onset post thrombotic syndrome and comparison of the onset kinetics of post thrombotic syndrome
Description
variables tested as prognostic factors of post thrombotic syndrome apparition : location of the upper pole of thrombus kinetic of thrombus lysis by duplex scan at 3 months Idiopathic nature of TED Delay of diagnostic of deep venous thrombosis Initial intensity of deep venous thrombosis symptoms Initial evolution of symptoms of deep venous thrombosis between J0 and 3 months Persistence of the symptoms at 3 months Patient's characteristics Kinetic of of Villalta score apparition ≥ 5 by survival curve Kinetic of post thrombotic syndrome apparition by Villalta score
Time Frame
24 months
Title
test for key factors in good compliance
Description
Compliance evaluation according to the 2 axes defined on third outcome measure and research of determinants of good compliance by specific questionnaire
Time Frame
24 months
Title
Adverse events
Description
description and comparison of the incidence of adverse events including unexpected adverse events, events expected with this type of disease (recurrence of the venous thromboembolic disease, recurrence of deep vein thrombosis, pulmonary embolism, superficial venous thrombosis, venous ulcer) and events possibly related to the study treatment (arterial decompensation passing to Lerich stage III or IV, skin intolerance)
Time Frame
24 months
Title
Subgroups analysis of the primary objective and secondary objectives according to the gender stratification criterion and age
Description
Stratification on age (more or less than 65 years-old) for testing the hypothesis by subgroups analysis of the benefit of a better adaptation of compression 25 mm Hg on older subjects, as suggested by S. Khan.
Time Frame
24 months
Title
superiority of 25 mmHg on 35 mmHg in preventing the onset of clinical post thrombotic syndrome
Description
superiority of 25 mmHg on 35 mmHg in preventing the onset of clinical post thrombotic syndrome. Outcome measure identical to primary endpoint
Time Frame
24 months
Title
sensitivity analysis of primary endpoint excluding patients with a differential diagnosis can explain a Villalta score ≥ 5
Description
sensitivity analysis of primary endpoint excluding patients with a differential diagnosis which could explain a Villalta score ≥ 5. Outcome measure identical to primary endpoint
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Patient (male/female) at least 18 years old Patient presenting with an initial episode of proximal deep vein thrombosis (DVT) confirmed by an additional examination (echo-Doppler scan) taken no more than 8 days previously : the proximal character defined by a DVT from the collecting trunk extending from the tibial-peroneal trunk to the inferior vena cava inclusive the unilateral character concerns only the proximal part. Patients with a distal DVT on the contralateral member the day of diagnosis can be included The notion of initial episode concerns only the proximal part. Patients with a preceding DVT limited to distal part can be included with no trophic disorders at baseline (CEAP class 4, 5 or 6 excluded) with or without pulmonary embolism Patient capable of benefiting from anticoagulant therapy of at least 3 months duration Available to participate in a clinical trial with a 24-month follow-up period and for which a delivery of study products may be possible throughout its participation (delivery possible only in Metropolitan France) Life expectancy greater than 24 months Volunteer to take part in the study, having signed the consent form after receiving sufficient information and the information leaflet Person affiliated to social security or the recipient of a similar scheme. non inclusion criteria Patients with at least one of these contraindications to compression treatment: phlegmasia cerulea dolens, septic thrombosis, product intolerance, allergic reaction to one of the components Arteritis obliterans stage III and IV of the lower limbs (IPS<0.6), Micro-angiopathy, advanced diabetes, Decompensated heart failure, Skin infections: anti-infective treatment must precede compression therapy, Weeping skin diseases of the leg. Compression treatment technically impossible during the study Patients presenting with bilateral venous thrombosis of the lower limbs. Patient having received fibrinolytic treatment, mechanical thrombo-aspiration or venous repermeation surgery for venous thrombosis justifying inclusion Patients having undergone mechanical interruption of the inferior vena cava. Patients for whom long-term elastic compression for the treatment of lymphatic venous insufficiency (patients with lymphoedema), for instance, is indicated prior to DVT. Patients with elastic compression for primary thromboprophylaxis of thromboembolic disease (TED) are eligible. Patients presenting with oedema unrelated to venous insufficiency or in whom oedema is likely to develop within 2 years. Patients receiving diuretic treatment for more than 3 months due to heart failure. Pregnant women Person deprived of liberty by a legal or administrative decision, person under legal protection. Patient currently participating in a clinical trial or having taken part in a clinical trial in the month preceding inclusion Patient presenting with a history of mental or psychiatric illness or any other factor restricting his/her ability to participate in an informed manner and in compliance with the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Luc BOSSON, MD, PhD
Organizational Affiliation
CIC Grenoble
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cabinet
City
Lyon
State/Province
Rhônes Alpes
ZIP/Postal Code
69003
Country
France
Facility Name
Cabinet
City
Aix Les Bains
ZIP/Postal Code
73100
Country
France
Facility Name
Cabinet
City
Alencon
ZIP/Postal Code
61000
Country
France
Facility Name
Clinique Victor PAUCHET
City
Amiens
ZIP/Postal Code
80000
Country
France
Facility Name
CHRU Amiens
City
Amiens
ZIP/Postal Code
80054
Country
France
Facility Name
Cabinet
City
Amiens
ZIP/Postal Code
80094
Country
France
Facility Name
Chu Angers
City
Angers
ZIP/Postal Code
49933
Country
France
Facility Name
Cabinet
City
Annecy
ZIP/Postal Code
74000
Country
France
Facility Name
Chra Annecy
City
Annecy
ZIP/Postal Code
74374
Country
France
Facility Name
Centre Hospitalier d'Armentieres
City
Armentieres
ZIP/Postal Code
59280
Country
France
Facility Name
CH Armentières
City
Armentieres
ZIP/Postal Code
59280
Country
France
Facility Name
Cabinet
City
Bordeaux
ZIP/Postal Code
33300
Country
France
Facility Name
Cabinet
City
Bourgoin Jallieu
ZIP/Postal Code
38300
Country
France
Facility Name
Ch Bourgoin-Jallieu
City
Bourgoin-Jallieu
ZIP/Postal Code
38300
Country
France
Facility Name
Hia Brest
City
Brest
ZIP/Postal Code
29200
Country
France
Facility Name
Chu Brest
City
Brest
ZIP/Postal Code
29609
Country
France
Facility Name
CHU
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
Cabinet
City
Carcassonne
ZIP/Postal Code
11000
Country
France
Facility Name
Cabinet
City
Chalon Sur Saone
ZIP/Postal Code
71100
Country
France
Facility Name
Ch Chalon Sur Saone
City
Chalon sur Saone
ZIP/Postal Code
71321
Country
France
Facility Name
CH de Chambéry
City
Chambery
ZIP/Postal Code
73000
Country
France
Facility Name
Cabinet
City
Clapiers
ZIP/Postal Code
34830
Country
France
Facility Name
Chu Clermont-Ferrand
City
Clermont-Ferrand
ZIP/Postal Code
63003
Country
France
Facility Name
CHU Gabriel Montpied
City
Clermont-ferrand
ZIP/Postal Code
63003
Country
France
Facility Name
Cabinet
City
Dijon
ZIP/Postal Code
21000
Country
France
Facility Name
Hôpital du bocage
City
Dijon
ZIP/Postal Code
21079
Country
France
Facility Name
Cabinet
City
Echirolles
ZIP/Postal Code
38130
Country
France
Facility Name
Cabinet
City
Genas
ZIP/Postal Code
69740
Country
France
Facility Name
Cabinet
City
Grenoble
ZIP/Postal Code
38000
Country
France
Facility Name
Chu Grenoble
City
Grenoble
ZIP/Postal Code
38043
Country
France
Facility Name
Cabinet
City
Hennebont
ZIP/Postal Code
56700
Country
France
Facility Name
Cabinet
City
Issy Les Moulineaux
ZIP/Postal Code
92130
Country
France
Facility Name
Ch La Rochelle
City
La Rochelle
ZIP/Postal Code
17000
Country
France
Facility Name
Cabinet
City
Lille
ZIP/Postal Code
59000
Country
France
Facility Name
Chru Lille
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Hopital Saint Philibert
City
Lomme
ZIP/Postal Code
59462
Country
France
Facility Name
CH Pierre-Bénite
City
Lyon
ZIP/Postal Code
69310
Country
France
Facility Name
Cabinet
City
Montbonnot St Martin
ZIP/Postal Code
38330
Country
France
Facility Name
Cabinet
City
Montelimar
ZIP/Postal Code
26200
Country
France
Facility Name
Cabinet
City
Montigny Les Metz
ZIP/Postal Code
57950
Country
France
Facility Name
Cabinet
City
Montlucon
ZIP/Postal Code
03100
Country
France
Facility Name
Chu Montpellier
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
CH Mâcon
City
Mâcon
ZIP/Postal Code
71018
Country
France
Facility Name
Chu Hotel Dieu
City
Nantes
ZIP/Postal Code
44039
Country
France
Facility Name
CHR Orléans
City
Orleans
ZIP/Postal Code
45067
Country
France
Facility Name
HEGP
City
Paris
ZIP/Postal Code
75015
Country
France
Facility Name
Hôpital St Joseph
City
Paris
ZIP/Postal Code
75674
Country
France
Facility Name
Cabinet
City
Peronne
ZIP/Postal Code
80200
Country
France
Facility Name
Cabinet
City
Saint-Aubin-sur-Scie
ZIP/Postal Code
76550
Country
France
Facility Name
Cabinet
City
Selestat
ZIP/Postal Code
67600
Country
France
Facility Name
Cabinet
City
St Alban
ZIP/Postal Code
31140
Country
France
Facility Name
Chu St Etienne
City
St Etienne
ZIP/Postal Code
42055
Country
France
Facility Name
Cabinet
City
Thonon Les Bains
ZIP/Postal Code
74200
Country
France
Facility Name
Chu Toulouse
City
Toulouse
ZIP/Postal Code
31059
Country
France
Facility Name
Cabinet
City
Tournefeuille
ZIP/Postal Code
31170
Country
France
Facility Name
Cabinet
City
Villeurbanne
ZIP/Postal Code
69100
Country
France
Facility Name
Cabinet
City
Vizille
ZIP/Postal Code
38220
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
12525804
Citation
Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg. 2003 Jan;25(1):1-5. doi: 10.1053/ejvs.2002.1778.
Results Reference
background
PubMed Identifier
10823257
Citation
Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000 May;83(5):657-60.
Results Reference
background
PubMed Identifier
19222476
Citation
Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol. 2009 May;145(3):286-95. doi: 10.1111/j.1365-2141.2009.07601.x. Epub 2009 Feb 13.
Results Reference
background
PubMed Identifier
8644983
Citation
Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996 Jul 1;125(1):1-7. doi: 10.7326/0003-4819-125-1-199607010-00001.
Results Reference
background
PubMed Identifier
9299855
Citation
Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, Bernardi E, Girolami B, Simioni P, Girolami A. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997 Jul-Aug;82(4):423-8.
Results Reference
background
PubMed Identifier
15269829
Citation
Gabriel F, Labios M, Portoles O, Guillen M, Corella D, Frances F, Martinez M, Gil J, Saiz C. Incidence of post-thrombotic syndrome and its association with various risk factors in a cohort of Spanish patients after one year of follow-up following acute deep venous thrombosis. Thromb Haemost. 2004 Aug;92(2):328-36. doi: 10.1160/TH03-11-0700.
Results Reference
background
PubMed Identifier
14718318
Citation
Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med. 2004 Jan 12;164(1):17-26. doi: 10.1001/archinte.164.1.17.
Results Reference
background
PubMed Identifier
12020185
Citation
Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med. 2002 May 27;162(10):1144-8. doi: 10.1001/archinte.162.10.1144.
Results Reference
background
PubMed Identifier
9072931
Citation
Bergqvist D, Jendteg S, Johansen L, Persson U, Odegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med. 1997 Mar 15;126(6):454-7. doi: 10.7326/0003-4819-126-6-199703150-00006.
Results Reference
background
PubMed Identifier
9074574
Citation
Brandjes DP, Buller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997 Mar 15;349(9054):759-62. doi: 10.1016/S0140-6736(96)12215-7.
Results Reference
background
PubMed Identifier
15313740
Citation
Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A, Bernardi E, Tormene D, Mosena L, Pagnan A, Girolami A. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 2004 Aug 17;141(4):249-56. doi: 10.7326/0003-4819-141-4-200408170-00004.
Results Reference
background
PubMed Identifier
8307217
Citation
Milne AA, Ruckley CV. The clinical course of patients following extensive deep venous thrombosis. Eur J Vasc Surg. 1994 Jan;8(1):56-9. doi: 10.1016/s0950-821x(05)80121-5.
Results Reference
background
PubMed Identifier
11054217
Citation
Partsch H, Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg. 2000 Nov;32(5):861-9. doi: 10.1067/mva.2000.110352.
Results Reference
background
PubMed Identifier
12871457
Citation
Kahn SR, Elman E, Rodger MA, Wells PS. Use of elastic compression stockings after deep venous thrombosis: a comparison of practices and perceptions of thrombosis physicians and patients. J Thromb Haemost. 2003 Mar;1(3):500-6. doi: 10.1046/j.1538-7836.2003.00098.x.
Results Reference
background
PubMed Identifier
11210954
Citation
Benko T, Cooke EA, McNally MA, Mollan RA. Graduated compression stockings: knee length or thigh length. Clin Orthop Relat Res. 2001 Feb;(383):197-203.
Results Reference
background
PubMed Identifier
16931066
Citation
Sajid MS, Tai NR, Goli G, Morris RW, Baker DM, Hamilton G. Knee versus thigh length graduated compression stockings for prevention of deep venous thrombosis: a systematic review. Eur J Vasc Endovasc Surg. 2006 Dec;32(6):730-6. doi: 10.1016/j.ejvs.2006.06.021. Epub 2006 Aug 23.
Results Reference
background
PubMed Identifier
17012004
Citation
Nelson EA, Harper DR, Prescott RJ, Gibson B, Brown D, Ruckley CV. Prevention of recurrence of venous ulceration: randomized controlled trial of class 2 and class 3 elastic compression. J Vasc Surg. 2006 Oct;44(4):803-8. doi: 10.1016/j.jvs.2006.05.051.
Results Reference
background
PubMed Identifier
17287629
Citation
Arpaia G, Cimminiello C, Mastrogiacomo O, de Gaudenzi E. Efficacy of elastic compression stockings used early or after resolution of the edema on recanalization after deep venous thrombosis: the COM.PRE Trial. Blood Coagul Fibrinolysis. 2007 Mar;18(2):131-7. doi: 10.1097/MBC.0b013e328011f2dd.
Results Reference
background
PubMed Identifier
18480967
Citation
Roumen-Klappe EM, den Heijer M, van Rossum J, Wollersheim H, van der Vleuten C, Thien T, Janssen MC. Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome. J Thromb Thrombolysis. 2009 May;27(4):400-5. doi: 10.1007/s11239-008-0229-7. Epub 2008 May 15.
Results Reference
background
PubMed Identifier
20880613
Citation
Delluc A, Gouedard C, De Saint Martin L, Garcia C, Roguedas AM, Bressollette L, Misery L, Mottier D, Le Gal G. [Incidence, risk factors and skin manifestations of post-thrombotic syndrome: a four-year follow-up of patients included in the EDITH study]. Rev Med Interne. 2010 Nov;31(11):729-34. doi: 10.1016/j.revmed.2010.07.018. Epub 2010 Sep 29. French.
Results Reference
background

Learn more about this trial

Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome

We'll reach out to this number within 24 hrs